Free Trial
NASDAQ:TLX

Telix Pharmaceuticals H1 2025 Earnings Report

Telix Pharmaceuticals logo
$14.20 +0.31 (+2.23%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$14.10 -0.10 (-0.70%)
As of 07/25/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telix Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
$0.22
Beat/Miss
N/A
One Year Ago EPS
N/A

Telix Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$316.69 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Telix Pharmaceuticals Announcement Details

Quarter
H1 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 21, 2025
Conference Call Time
7:00PM ET

Conference Call Resources

Telix Pharmaceuticals Earnings Headlines

William Blair Issues Optimistic Forecast for TLX Earnings
Elon Musk: “This will transform civilization as we know it.”
Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by 2025, robots will shift from novelty to necessity — disrupting nearly every industry in their path. But one overlooked sector could become the real winner… and one little-known company may be the best way to get ahead of the boom.
See More Telix Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telix Pharmaceuticals and other key companies, straight to your email.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ:TLX). engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

View Telix Pharmaceuticals Profile

More Earnings Resources from MarketBeat